Info

Clinical trials for breast cancer in Romania

Which trials are taking patients now, in which cities, and what to ask your doctor. The official record stays with the national agency.

← All cancer types

How to read this list

Each row is an authorised trial looking for participants. The plain-language title is written by our editorial team, and underneath it you can see the original registry title — so you can check for yourself that we did not change the meaning. We cannot tell you whether you are eligible, and we do not publish the hospital name: the international registry does not carry it, and a wrong name would send you to a room where nobody expects you. For the centre and the team's contact details, open the official record.

Trials recruiting now

0 of 15 titles have been rewritten in plain language by our editorial team. The rest still show the registry's protocol wording.

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

A treatment is being testedPhase 3

Running in: Baia Mare · Brașov · Cluj-Napoca · Constanța · Craiova · Florești — and 5 more

See the official record ↗ NCT05774951

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

A treatment is being testedPhase 3

Running in: București · Cluj-Napoca · Craiova · Florești · Iași · Oradea — and 5 more

See the official record ↗ NCT05952557

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

A treatment is being testedPhase 2

Running in: Bistrița · București · Institutul Oncologic Cluj, Cluj-Napoca · Centrul de Oncologie "Sfântul Nectarie", Craiova · Centrul de Radioterapie Amethyst Timis, Dumbrăviţa · SC Radiotherapy Center Cluj SRL, Florești — and 3 more

See the official record ↗ NCT06926868

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

A treatment is being testedPhase 3

Running in: Clinical Trial Site, Brașov · Clinical Trial Site, București · Clinical Trial Site, Cluj-Napoca · Clinical Trial Site, Craiova · Clinical Trial Site, Iași · Clinical Trial Site, Oradea — and 1 more

See the official record ↗ NCT06016738

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

A treatment is being testedPhase 3

Running in: Spitalul Clinic Filantropia, București · Amethyst Cluj, Cluj County · Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca · Centrul de Oncologie Sfantul Nectarie, Craiova · Institutul Regional de Oncologie Iasi, Iași · Centrul de Oncologie Oncohelp, Timișoara

See the official record ↗ NCT06065748

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

A treatment is being testedPhase 3

Running in: Spitalul Clinic Filantropia, București · Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Oncolab - Medical Oncology, Craiova · Radiotherapy Center Cluj, Florești · Institutul Regional de Oncologie Iasi - Medical Oncology, Iași · Oncomed - Medical Oncology, Timișoara

See the official record ↗ NCT06492616

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

A treatment is being testedPhase 3

Running in: Centrul de Oncologie Sf Nectarie - Medical Oncology, Baia Mare · Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, București · Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti, Cluj-Napoca · Onco Clinic Consult, Craiova · Radiotherapy Center Cluj, Florești · Centrul de Oncologie Euroclinic, Iași

See the official record ↗ NCT06757634

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

A treatment is being testedPhase 3

Running in: Spitalul Clinic Filantropia ( Site 4703), București · Institutul Oncologic Cluj ( Site 4701), Cluj-Napoca · S.C. Radiotherapy Center Cluj S.R.L ( Site 4705), Comuna Floresti · Centrul de Oncologie "Sfântul Nectarie" ( Site 4702), Craiova · Spitalul Municipal Schuller Ploiești ( Site 4707), Ploiești · Cabinet Medical Oncomed ( Site 4704), Timișoara

See the official record ↗ NCT06841354

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

A treatment is being testedPhase 3

Running in: Clinical Trial Site, București · Clinical Trial Site, Cluj-Napoca · Clinical Trial Site, Craiova · Clinical Trial Site, Iași · Clinical Trial Site, Ovidiu · Clinical Trial Site, Timișoara

See the official record ↗ NCT07085767

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

A treatment is being testedPhase 3

Running in: Centrul Medical Focus, București · Radiotherapy Center Cluj, Cluj-Napoca · Onco Clinic Consult SA, Craiova · Gral Medical SRL, Pitești · OncoMed Oncology Center, Timișoara

See the official record ↗ NCT05696626

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

A treatment is being testedPhase 3

Running in: Spitalul Clinic Filantropia ( Site 4801), București · Institutul Oncologic Cluj ( Site 4802), Cluj-Napoca · Institutul Regional de Oncologie ( Site 4805), Iași · Cabinet Medical Oncomed ( Site 4803), Timișoara

See the official record ↗ NCT06966700

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

A treatment is being testedPhase 3

Running in: Clinica Neolife Băneasa București, București · Institute of Oncology "Prof Dr Ion Chiricuta", Cluj-Napoca · Oncomed SRL - Oncology Center, Timișoara

See the official record ↗ NCT05232916

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

A treatment is being testedPhase 3

Running in: Spitalul Clinic Filantropia ( Site 1703), București · Institutul Oncologic Cluj ( Site 1701), Cluj-Napoca · SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 1702), Florești

See the official record ↗ NCT06312176

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

A treatment is being testedNo phase

Running in: Institute of Oncology ''Prof. Dr. Ion Chiricuță'' of Cluj-Napoca, Cluj-Napoca

See the official record ↗ NCT05890677

International Prospective REgistry on Pre-pectorAl Breast REconstruction

Observational study — you do not receive a new treatment

Running in: Prof. Dr. Ion Chiricuta Institute of Oncology, Cluj-Napoca

See the official record ↗ NCT05817175

Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Read automatically, last on 31 Jul 2026.

Worth reading before you talk to your doctor

Material from our library to help you prepare your questions.

Where the official information lives

The road ends at the registry, not with us. That is where each trial's full record is — including the things we do not publish.

Studii Clinice România (ANMDMR) ↗ClinicalTrials.gov ↗

Where the data on this page comes from

The counts are read automatically from ClinicalTrials.gov and show trials marked there as recruiting, with at least one site in Romania. We do not verify each one by hand, and we cannot guarantee that a trial marked “recruiting” is still taking patients today — the registry lags behind what happens in the hospital. For any decision, the official record and your doctor have the final word.